CFDA Cracking Down on Labeling—36% Defects Have Labelling Issues

Weekly CFDA News Roundup (June 11th to June 18th) 
June 23, 2018
Historical Medical Device Changes from NMPA (CFDA) Announced Today
June 26, 2018

CFDA Cracking Down on Labeling—36% Defects Have Labelling Issues

On June 22, CFDA published Quality Notice #47 and identified 64 defects for 9 types of medical devices: nerve and muscle stimulator, ultrasonic atomizer, disposable vaginal dilator, insulin pimp, oxygen concentrator, maxillofacial X-ray, surgical needle, etc. Some affected devices are to be voluntarily recalled by manufacturers.

China Med Device, LLC can help you design the electronic file for SDA (CFDA) compliance labels in Chinese.  In addition, we can help and implement these labels on the products to meet SDA requirements. Please email info@ChinaMedDevice.com for more information.

All the observations were classified by the following reasons: 

23 labeling issues, 21 design issues, 12 management problems and 6 record deviations and 2 manufacturing defects.

 

Among the devices with labeling issues, 3 imported ones were affected:

Topcon (Japan): refractometer

Marutakatech (Japan): high frequency electron apparatus

PaloDEx (Finland): maxillofacial X-ray

 

CFDA started to publish Medical Device Quality Notice since February 2016 to improve the quality system and post market compliance of manufacturers in China. A total of 47 notices have been issued in 2 and a half years.

It should be noted that the post-market surveillance, including sampling, inspection and supervision of Corrective and Preventive Action (CAPA), are carried by local CFDA offices where the manufacturers are registered.

Shanghai quarterly recall report published in early April showed 15% recalls have labeling issues.

 

Keep yourself updated with CFDA News Roundup, click HERE to opt-in. For market access newsletter, click HERE. For CRO services in China, click HERE.  

 

About China Med Device, LLC  

China Med Device, LLC provides turn-key solutions for western medical device/IVD companies to enter China with regulation and commercialization services. Our CFDA regulatory services cover strategy, premarket submission, clinical evaluation, CRO, QA and post market compliance. We are experienced in handling innovation approvals and priority reviews. Our commercial services cover market assessment research, reimbursement, partnership, distribution qualification and management. We have offices in Beijing, Suzhou and Boston. Our management team has 100+ years of combined experience in medical device and IVD and has been involved with 1,000+ CFDA certificates and 200+ companies’ success.